Securities Code: 300122 Securities Abbreviation: Zhifei Biological Announcement No.: 2026-25
Chongqing Zhifei Biological Products Co., Ltd. Announcement on Accrual of Asset Impairment Provisions for 2025
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as the "Company") held the eleventh meeting of the sixth Board of Directors on April 26, 2026, which reviewed and approved the "Proposal on Accrual of Asset Impairment Provisions for 2025". The details are hereby announced as follows:
I. Overview of Accrual of Asset Impairment Provisions
To truly reflect the Company's financial position and asset value, in accordance with the "Accounting Standards for Business Enterprises," the "Shenzhen Stock Exchange GEM Stock Listing Rules," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 2 - Norms for the Operation of GEM Listed Companies," the Company has assessed whether there are any signs of impairment for all assets as of December 31, 2025.
Based on the principle of prudence, for assets with signs of impairment, the Company conducts impairment tests according to the methods stipulated in the "Accounting Standards for Business Enterprises" and the Company's accounting policies. For assets with confirmed signs of impairment, asset impairment provisions are accrued in accordance with relevant regulations. After calculation, the total amount of asset impairment losses accrued this time is RMB 1,412,815.88 million, as detailed below:
| Project | Amount (RMB million) |
|---|---|
| Credit impairment loss | 50,973.00 |
| Inventory price decline provision and contract performance obligation impairment provision | 1,361,842.88 |
| Total | 1,412,815.88 |
II. Confirmation Standards and Accrual Methods for Asset Impairment Provisions This Time